Hosokawa T, Ogawa K, Otani Y, Kajiwara T
Oncol Rep. 1994 Jan;1(1):93-5.
Irsogladine Maleate intensifies the degree of intercellular contact so we expected that a combination of Irsogladine Maleate and UFT would cause tumor-reducing effect and normalization of the malignant cells. A combination of Irsogladine Maleate and UFT was administered to 2 patients with inoperable gastric cancer (Case 1: An 83-year-old male: Borrmann type I, Case 2: A 93-year-old female: A relatively wide early gastric cancer), marked tumor reduction was obtained in both cases. The doses administered were 4 mg/day of Irsogladine Maleate and 200 mg/day of UFT.
马来酸伊索拉定增强细胞间接触程度,因此我们预期马来酸伊索拉定与优福定联合使用会产生肿瘤缩小效应并使恶性细胞正常化。对2例无法手术的胃癌患者(病例1:一名83岁男性,Borrmann I型;病例2:一名93岁女性,相对较宽的早期胃癌)给予马来酸伊索拉定与优福定联合治疗,两例均获得显著的肿瘤缩小。给药剂量为马来酸伊索拉定4mg/天和优福定200mg/天。